D J Pinato1, J Howell1,2,3,4, R Ramaswami1, R Sharma1. 1. Division of Surgery and Cancer, Hammersmith Campus of Imperial College London, London, UK. 2. Centre for Population Health, MacFarlane-Burnet Institute, Melbourne, VIC, Australia. 3. Department of Medicine, Royal Melbourne Hospital and St Vincent's Hospital, Melbourne, VIC, Australia. 4. University of Melbourne, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC), for which trans-arterial chemoembolization (TACE) constitutes the standard of care, is a patient subgroup with significant heterogeneity in clinical outcome. Sources of variation relate to differences in tumour burden, hepatic reserve, ethnicity and treatment modalities. Increasing research efforts have been dedicated to minimise the clinical diversity of this patient population and enhance optimal provision of treatment. AIM: To comprehensively review the diverse prognostic models that have been proposed to refine the prognostic prediction of patients with HCC undergoing TACE. RESULTS: A number of prognostic algorithms (HAP, ART, ABCR score and many others) have shown potential to address the clinical heterogeneity characterising patients with intermediate-stage HCC and facilitate early identification of patients with poor prognostic features in whom alternative treatments or best supportive care might be more appropriate than TACE. CONCLUSIONS: While an improved characterisation of intermediate-stage HCC is a highly important clinical aim, current evidence suggests that novel prognostic algorithms in this patient population may offer potential benefits but non-negligible challenges in the provision of TACE. This review summarises the currently available evidence to facilitate the development of precision oncology in intermediate-stage HCC.
BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC), for which trans-arterial chemoembolization (TACE) constitutes the standard of care, is a patient subgroup with significant heterogeneity in clinical outcome. Sources of variation relate to differences in tumour burden, hepatic reserve, ethnicity and treatment modalities. Increasing research efforts have been dedicated to minimise the clinical diversity of this patient population and enhance optimal provision of treatment. AIM: To comprehensively review the diverse prognostic models that have been proposed to refine the prognostic prediction of patients with HCC undergoing TACE. RESULTS: A number of prognostic algorithms (HAP, ART, ABCR score and many others) have shown potential to address the clinical heterogeneity characterising patients with intermediate-stage HCC and facilitate early identification of patients with poor prognostic features in whom alternative treatments or best supportive care might be more appropriate than TACE. CONCLUSIONS: While an improved characterisation of intermediate-stage HCC is a highly important clinical aim, current evidence suggests that novel prognostic algorithms in this patient population may offer potential benefits but non-negligible challenges in the provision of TACE. This review summarises the currently available evidence to facilitate the development of precision oncology in intermediate-stage HCC.
Authors: Gauri Mishra; Anouk Dev; Eldho Paul; Wa Cheung; Jim Koukounaras; Ashu Jhamb; Ben Marginson; Beng Ghee Lim; Paul Simkin; Adina Borsaru; James Burnes; Mark Goodwin; Vivek Ramachandra; Manfred Spanger; John Lubel; Paul Gow; Siddharth Sood; Alexander Thompson; Marno Ryan; Amanda Nicoll; Sally Bell; Ammar Majeed; William Kemp; Stuart K Roberts Journal: BMC Cancer Date: 2020-05-29 Impact factor: 4.430
Authors: David J Pinato; Matthew W Brown; Sebastian Trousil; Eric O Aboagye; Jamie Beaumont; Hua Zhang; Helen M Coley; Francesco A Mauri; Rohini Sharma Journal: Br J Cancer Date: 2019-02-15 Impact factor: 7.640
Authors: Claudia A M Fulgenzi; Thomas Talbot; Sam M Murray; Marianna Silletta; Bruno Vincenzi; Alessio Cortellini; David J Pinato Journal: Curr Treat Options Oncol Date: 2021-08-23
Authors: Bruno Christ; Uta Dahmen; Karl-Heinz Herrmann; Matthias König; Jürgen R Reichenbach; Tim Ricken; Jana Schleicher; Lars Ole Schwen; Sebastian Vlaic; Navina Waschinsky Journal: Front Physiol Date: 2017-11-14 Impact factor: 4.566